10-Q: enGene Holdings Inc. Reports Q1 2025 Financial Results, Highlights Detalimogene Development

enGene Holdings Inc. reports increased R&D spending as it advances its detalimogene program for bladder cancer treatment.

Summary

• enGene Holdings Inc., a clinical-stage biotechnology company, released its financial results for the first quarter ended January 31, 2025.
• The company is focused on developing genetic medicines using its DDX gene delivery platform, with its lead product candidate, detalimogene voraplasmid, targeting bladder cancer.
• The company's net loss for the quarter was $24.6 million, compared to $10.7 million for the same period in 2024.
• Research and development expenses increased significantly to $20.0 million from $5.6 million year-over-year, driven by the advancement of the detalimogene LEGEND study.
• As of January 31, 2025, enGene had $272.8 million in cash, cash equivalents, and marketable securities.
• The company believes its current resources will be sufficient to fund operations for at least the next 12 months.
• enGene is planning to file a Biologics License Application (BLA) with the FDA in mid-2026 for detalimogene.
• The company is also exploring the clinical application of detalimogene to other forms of NMIBC.
• The company is undertaking ongoing remediation efforts that include establishing adequate review and approval processes and procedures based on roles and responsibilities of each team member; implementing a risk assessment over financial reporting controls; designing and implementing policy, procedures and controls around key business and financial reporting process; implementing new software tools with adequate set up to ensure segregation of duties; and engaging a professional accounting services firm to help with the documentation and assessment of our internal controls for complying with the Sarbanes-Oxley Act.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While the company has a strong cash position and is progressing with its clinical program, the increasing net loss and material weaknesses in internal control over financial reporting raise concerns.

Positives

• The company has a substantial amount of cash, cash equivalents, and marketable securities ($272.8 million) to fund operations for at least the next 12 months.
• The company is making progress on its lead product candidate, detalimogene, with plans to file a BLA with the FDA in mid-2026.
• The company is expanding the clinical application of detalimogene to other forms of NMIBC.
• The company is undertaking ongoing remediation efforts to address material weaknesses in internal control over financial reporting.

Negatives

• The company experienced a significant increase in net loss, from $10.7 million to $24.6 million year-over-year.
• The company has incurred significant operating losses and negative cash flows from operations since its inception and anticipates such losses and negative cash flows will continue for the foreseeable future.
• The company's disclosure controls and procedures were not effective due to the remaining unremediated material weaknesses in internal controls over financial reporting.

Risks

• The company's future success is heavily dependent on the success of detalimogene.
• The company may be adversely affected by changes in domestic and foreign business, market, financial, political, geopolitical, legal conditions and laws and regulations.
• The company may not be able to obtain additional funding on a timely basis.
• The company's ability to raise additional funds may be adversely impacted by potential worsening global economic conditions and disruptions to and volatility in the credit and financial markets in the United States and worldwide.
• The company's disclosure controls and procedures were not effective due to the remaining unremediated material weaknesses in internal controls over financial reporting.

Future Outlook

The company expects to continue to incur significant expenses and increasing operating losses for the foreseeable future as it advances the ongoing LEGEND study of detalimogene, including the pivotal cohort of patients with BCG-unresponsive NMIBC, to completion; execute on its plan to file a Biologics License Application with the FDA in mid-2026; and pursue potential pipeline expansion via additional detalimogene development opportunities and other compounds.

Management Comments

• The company believes that its existing cash and cash equivalents as of January 31, 2025 will be sufficient to fund its operating expenses, debt obligations, and capital expenditure requirements for at least the next 12 months from the issuance date of the condensed consolidated financial statements included within this Quarterly Report.

Industry Context

enGene is operating in the competitive biotechnology industry, specifically focusing on genetic medicines for cancer treatment. The company's detalimogene program targets a significant unmet need in bladder cancer, particularly in patients unresponsive to BCG treatment. The success of the LEGEND study and the planned BLA filing are critical milestones for the company's future growth and market position.

Comparison to Industry Standards

• It is difficult to compare enGene's results to industry standards due to its unique DDX gene delivery platform and focus on detalimogene.
• However, other companies in the gene therapy space, such as bluebird bio and CRISPR Therapeutics, are also investing heavily in research and development, with similar increases in R&D expenses as they advance their clinical programs.
• enGene's cash position is relatively strong compared to other small-cap biotech companies, providing a runway for continued development of detalimogene.
• However, the company's increasing net loss and the presence of material weaknesses in internal control over financial reporting are areas of concern that need to be addressed.

Stakeholder Impact

• Shareholders may be concerned about the increasing net loss and the material weaknesses in internal control over financial reporting.
• Employees may be affected by the company's efforts to remediate the material weaknesses in internal control over financial reporting.
• Customers (potential patients) may benefit from the company's progress in developing detalimogene as a treatment for bladder cancer.
• Suppliers and creditors may be affected by the company's ability to secure additional funding and manage its cash flow.

Next Steps

• Continue enrolling patients in the LEGEND study of detalimogene.
• File a Biologics License Application (BLA) with the FDA in mid-2026 for detalimogene.
• Pursue potential pipeline expansion via additional detalimogene development opportunities and other compounds.
• Remediate the material weaknesses in internal control over financial reporting.

Key Dates